Advertisement
| axovant gene therapies ltd: The Venture Alchemists Rob Lalka, 2024-05-14 We once idolized tech entrepreneurs for creating innovations that seemed like modern miracles. Yet our faith has been shattered. We now blame them for spreading lies, breaking laws, and causing chaos. Yesterday’s Silicon Valley darlings have become today’s Big Tech villains. Which is it? Are they superheroes or scoundrels? Or is it more complicated, some blend of both? In The Venture Alchemists, Rob Lalka demystifies how tech entrepreneurs built empires that made trillions. Meta started as a cruel Halloween prank, Alphabet began as a master’s thesis that warned against corporate deception, and Palantir came from a campus controversy over hateful speech. These largely forgotten origin stories show how ordinary fears and youthful ambitions shaped their ventures—making each tech tale relatable, both wonderfully and tragically human. Readers learn about the adversities tech entrepreneurs overcame, the troubling tradeoffs they made, and the tremendous power they now wield. Using leaked documents and previously unpublished archival material, Lalka takes readers inside Big Tech’s worst exploitations and abuses, alongside many good intentions and moral compromises. But this story remains unfinished, and The Venture Alchemists ultimately offers hope from the people who, decades ago, warned about the risks of the emerging Internet. Their insights illuminate a path toward more responsible innovations, so that technologies aren’t dangerous weapons but valuable tools that ensure progress, improve society, and enhance our daily lives. |
| axovant gene therapies ltd: The Behavioral Neurology of Dementia Bruce L. Miller, Bradley F. Boeve, 2016-11-17 Distils the most valuable discoveries in dementia research into clear, insightful chapters written by international experts. |
| axovant gene therapies ltd: Dementia with Lewy Bodies John O'Brien, David Ames, Ian McKeith, Edmond Chiu, 2005-11-29 Filling a noticeable gap in the market for a new text solely focused on Dementia with Lewy Bodies, this book discusses cutting-edge topics covering the condition from diagnosis to management, as well as what is known about the neurobiological changes involved. With huge progress having been made over the last decade in terms of the disorder |
| axovant gene therapies ltd: Parkinson's Disease Jason S. Hawley, Melissa J. Armstrong, William J. Weiner, 2014-02 Parkinson's Disease: Improving Patient Care is a clinically-focused text for healthcare professionals involved in everyday management of Parkinson's disease patients. Concise chapters and abundant tables make it easy to read or use as a handy reference. |
| axovant gene therapies ltd: Coding Literacy Annette Vee, 2017-07-28 How the theoretical tools of literacy help us understand programming in its historical, social and conceptual contexts. The message from educators, the tech community, and even politicians is clear: everyone should learn to code. To emphasize the universality and importance of computer programming, promoters of coding for everyone often invoke the concept of “literacy,” drawing parallels between reading and writing code and reading and writing text. In this book, Annette Vee examines the coding-as-literacy analogy and argues that it can be an apt rhetorical frame. The theoretical tools of literacy help us understand programming beyond a technical level, and in its historical, social, and conceptual contexts. Viewing programming from the perspective of literacy and literacy from the perspective of programming, she argues, shifts our understandings of both. Computer programming becomes part of an array of communication skills important in everyday life, and literacy, augmented by programming, becomes more capacious. Vee examines the ways that programming is linked with literacy in coding literacy campaigns, considering the ideologies that accompany this coupling, and she looks at how both writing and programming encode and distribute information. She explores historical parallels between writing and programming, using the evolution of mass textual literacy to shed light on the trajectory of code from military and government infrastructure to large-scale businesses to personal use. Writing and coding were institutionalized, domesticated, and then established as a basis for literacy. Just as societies demonstrated a “literate mentality” regardless of the literate status of individuals, Vee argues, a “computational mentality” is now emerging even though coding is still a specialized skill. |
| axovant gene therapies ltd: Spotify Teardown Maria Eriksson, Rasmus Fleischer, Anna Johansson, Pelle Snickars, Patrick Vonderau, 2019-02-19 An innovative investigation of the inner workings of Spotify that traces the transformation of audio files into streamed experience. Spotify provides a streaming service that has been welcomed as disrupting the world of music. Yet such disruption always comes at a price. Spotify Teardown contests the tired claim that digital culture thrives on disruption. Borrowing the notion of “teardown” from reverse-engineering processes, in this book a team of five researchers have playfully disassembled Spotify's product and the way it is commonly understood. Spotify has been hailed as the solution to illicit downloading, but it began as a partly illicit enterprise that grew out of the Swedish file-sharing community. Spotify was originally praised as an innovative digital platform but increasingly resembles a media company in need of regulation, raising questions about the ways in which such cultural content as songs, books, and films are now typically made available online. Spotify Teardown combines interviews, participant observations, and other analyses of Spotify's “front end” with experimental, covert investigations of its “back end.” The authors engaged in a series of interventions, which include establishing a record label for research purposes, intercepting network traffic with packet sniffers, and web-scraping corporate materials. The authors' innovative digital methods earned them a stern letter from Spotify accusing them of violating its terms of use; the company later threatened their research funding. Thus, the book itself became an intervention into the ethics and legal frameworks of corporate behavior. |
| axovant gene therapies ltd: Neurodegeneration Dennis Dickson, Roy O. Weller, 2011-11-07 Most textbooks on neurodegenerative disorders have used a classification scheme based upon either clinical syndromes or anatomical distribution of the pathology. In contrast, this book looks to the future and uses a classification based upon molecular mechanisms, rather than clinical or anatomical boundaries. Major advances in molecular genetics and the application of biochemical and immunocytochemical techniques to neurodegenerative disorders have generated this new approach. Throughout most of the current volume, diseases are clustered according to the proteins that accumulate within cells (e.g. tau, α-synuclein and TDP-43) and in the extracellular compartments (e.g. β-amyloid and prion proteins) or according to a shared pathogenetic mechanism, such as trinucleotide repeats, that are a feature of specific genetic disorders. Chapters throughout the book conform to a standard lay-out for ease of access by the reader and are written by a panel of International Experts Since the first edition of this book, major advances have been made in the discovery of common molecular mechanisms between many neurodegenerative diseases most notably in the frontotemporal lobar degenerations (FTLD) and motor neuron disease or amyotrophic lateral sclerosis. This book will be essential reading for clinicians, neuropathologists and basic neuroscientists who require the firm up-to-date knowledge of mechanisms, diagnostic pathology and genetics of Neurodegenerative diseases that is required for progress in therapy and management. |
| axovant gene therapies ltd: Disorders of Movement Davide Martino, Alberto J. Espay, Alfonso Fasano, Francesca Morgante, 2015-12-17 This concise but comprehensive book will help interested readers in the health care professions to navigate their way through the jungle of movement disorders, including the potentially complex differential diagnosis and management. The different disorders are discussed in individual sections that explain how to examine the patient and recognize the disorder from its basic phenomenology, how to confirm a diagnosis, how to distinguish a particular disorder from related conditions, and how to treat each disorder effectively. The book makes liberal use of diagrams, algorithms, tables, summary boxes, and illustrations to facilitate solution of clinical problems at the bedside and to solidify previously learned clinical and therapeutic concepts. It will be of interest to a broad audience of health professionals, scientists, and medical students. |
| axovant gene therapies ltd: PDQ Statistics Geoffrey R. Norman, David L. Streiner, PhD, 2003-01-01 The third edition of PDQ Statistics provides an overview of all major statistical methods, giving the reader a good understanding of statistics and how they are used in research articles. It covers the major categories – variable and descriptive statistics, parametric statistics, non-parametric statistics, and multivariate statistics. The explanations are clear, succinct, and loaded with practical examples. |
| axovant gene therapies ltd: Encyclopedia of Psychopharmacology Ian Stolerman, 2010-07-31 Here is a broad overview of the central topics and issues in psychopharmacology, biological psychiatry and behavioral neurosciences, with information about developments in the field, including novel drugs and technologies. The more than 2000 entries are written by leading experts in pharmacology and psychiatry and comprise in-depth essays, illustrated with full-color figures, and are presented in a lucid style. |
| axovant gene therapies ltd: Free Energy Calculations Christophe Chipot, Andrew Pohorille, 2007-01-08 Free energy constitutes the most important thermodynamic quantity to understand how chemical species recognize each other, associate or react. Examples of problems in which knowledge of the underlying free energy behaviour is required, include conformational equilibria and molecular association, partitioning between immiscible liquids, receptor-drug interaction, protein-protein and protein-DNA association, and protein stability. This volume sets out to present a coherent and comprehensive account of the concepts that underlie different approaches devised for the determination of free energies. The reader will gain the necessary insight into the theoretical and computational foundations of the subject and will be presented with relevant applications from molecular-level modelling and simulations of chemical and biological systems. Both formally accurate and approximate methods are covered using both classical and quantum mechanical descriptions. A central theme of the book is that the wide variety of free energy calculation techniques available today can be understood as different implementations of a few basic principles. The book is aimed at a broad readership of graduate students and researchers having a background in chemistry, physics, engineering and physical biology. |
| axovant gene therapies ltd: Epilepsy and the Interictal State Erik K. St Louis, David M. Ficker, Terence J. O'Brien, 2015-03-02 Epilepsy care traditionally focuses on seizures, yet for most epilepsy sufferers, other interictal factors such as mood, cognitive abilities, and treatment adverse effects most influence how they feel and function day to day. Epilepsy and the Interictal State is a practical and comprehensive text that covers quality of life issues, cognition and therapy, adverse effects of epilepsy treatments, mood state and psychiatric co-morbidity and general health aspects of epilepsy. Each chapter employs a standard structure providing background, epidemiology, pathophysiology, etiology, diagnosis, treatment, prognosis and further practical advice. From an international team of expert editors and contributors, Epilepsy and the Interictal State is a valuable resource for specialist epileptologists and neurologists, as well as for neurosurgeons, neurology nurses, psychiatrists, family physicians and general practitioners. |
| axovant gene therapies ltd: Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders Adeboye Adejare, 2025-09-01 Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease, 2nd Edition examines the drug discovery process for neurodegenerative diseases by focusing specifically on Alzheimer's Disease and illustrating the paradigm necessary to ensure future research and treatment success. The new edition of this book is updated with the most recent developments around the therapeutic strategies for drug discovery like amyloid hypothesis, tau, apo E, insulin, and others. It also includes a new chapter on drug delivery to the brain. The content covers diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more to provide a holistic approach to the discovery, development, and treatment of Alzheimer's Disease. Through its coverage of the latest research in targeted drug design, preclinical studies, and mouse and rat models, the book is a must-have resource for all pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers working in this area. Pharmaceutical researchers will benefit from the updated coverage on therapeutic approaches to neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, multiple sclerosis, frontotemporal disorder, Huntington's diseases and many more. Patients and advocacy groups can also benefit from the overview of current treatment options and the scientific progress in the field.• Covers Monoclonal Antibodies approaches• Provides a compilation of chemical considerations required in drug discovery for thetreatment of neurodegenerative disorders• Explores how in vitro and in vivo models translate to human physiology |
| axovant gene therapies ltd: Restless Legs Syndrome/Willis Ekbom Disease Mauro Manconi, Diego García-Borreguero, 2017-05-07 Due to the fact that Restless Legs Syndrome/Willis-Ekbom Disease is usually a chronic condition, this book aims to provide physicians with the necessary tools for the long-term management of patients with RLS. The first part of the book addresses the various comorbidities and long-term consequences of RLS on life quality, sleep, cognitive, psychiatric and cardiovascular systems, while the second part focuses on the management of long-term treatment and the drug-induced complications in primary RLS and in special populations. Written by experts in the field, this practical resource offers a high-quality, long-term management of RLS for neurologists, sleep clinicians, pulmonologists and other healthcare professionals. |
| axovant gene therapies ltd: Brain Banking , 2018-02-27 Brain Banking, Volume 150, serves as the only book on the market offering comprehensive coverage of the functional realities of brain banking. It focuses on brain donor recruitment strategies, brain bank networks, ethical issues, brain dissection/tissue processing/tissue dissemination, neuropathological diagnosis, brain donor data, and techniques in brain tissue analysis. In accordance with massive initiatives, such as BRAIN and the EU Human Brain Project, abnormalities and potential therapeutic targets of neurological and psychiatric disorders need to be validated in human brain tissue, thus requiring substantial numbers of well characterized human brains of high tissue quality with neurological and psychiatric diseases. - Offers comprehensive coverage of the functional realities of brain banking, with a focus on brain donor recruitment strategies, brain bank networks, ethical issues, and more - Serves as a valuable resource for staff in existing brain banks by highlighting best practices - Enhances the sharing of expertise between existing banks and highlights a range of techniques applicable to banked tissue for neuroscience researchers - Authored by leaders from brain banks around the globe – the broadest, most expert coverage available |
| axovant gene therapies ltd: Clinical Epileptology Nyla Shelton, 2021-11-16 Epileptology is a specialization under neurology which deals with the treatment of epilepsy. It is the study of epileptic seizures and seizure disorders, and anticonvulsants. Epilepsy is a group of neurological disorders. Recurrent epileptic seizures are the main signs of epilepsy. These are episodes that can vary from long periods of vigorous shaking to short and nearly undetectable periods. They are caused by abnormal electrical activity in the brain. Generally, an epileptologist is not required for the treatment of all seizure disorders and is consulted only if the seizures do not stop, even after the treatment from a regular neurologist. Epileptic seizures occur due to excessive and abnormal activity in the brain. Different approaches, evaluations, methodologies and advanced studies on epileptology have been included in this book. It strives to provide a fair idea about this discipline and to help develop a better understanding of this field. This book will provide comprehensive knowledge to the readers. |
| axovant gene therapies ltd: Biomarkers in Psychiatry Judith Pratt, Jeremy Hall, 2019-01-05 This volume addresses one of the Holy Grails in Psychiatry, namely the evidence for and potential to adopt ‘Biomarkers’ for prevention, diagnosis, and treatment responses in mental health conditions. It meshes together state of the art research from international renowned pre-clinical and clinical scientists to illustrate how the fields of anxiety disorders, depression, psychotic disorders, and autism spectrum disorder have advanced in recent years. |
| axovant gene therapies ltd: Education about Mental Health and Illness Marc H.M. Hermans, Tan Chay-Hoon, Edmond Pi, 2019-05-24 This book highlights the best educational practices for the professionals dealing with mental health and illness. While attempting an overall review of the current state-of-the-art in psychiatry education, the book focuses on recent developments and controversies in undergraduate and postgraduate psychiatric education around the globe. |
| axovant gene therapies ltd: Alzheimer's Disease Drug Development Jeffrey Cummings, Jefferson Kinney, Howard Fillit, 2022-03-31 Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models. |
| axovant gene therapies ltd: Cerebrospinal Fluid Biomarkers Charlotte E. Teunissen, Henrik Zetterberg, 2022-05-19 This volume covers the latest methods used in clinical neurochemistry laboratories for both clinical practice and research. Chapters in this book discuss topics such as techniques for cerebrospinal fluid (CSF) collection, pre-analytical processing, and basic CSF analysis; an examination of biomarkers including ELISA and automated immunochemical assays for amyloid and tau markers for Alzheimer’s disease; the analysis of neurofilaments by digital ELISA; and an example of successful novel immunoassay development. In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Cutting-edge and thorough, Cerebrospinal Fluid Biomarkers is a valuable resource for clinicians and researchers to use in CSF labs and CSF courses. |
| axovant gene therapies ltd: Neuromuscular Disorders: Management and Treatment E-Book Tulio E. Bertorini, 2010-09-08 Neuromuscular Disorders presents a multi-disciplinary approach to the management and therapeutic treatment of the full range of neuromuscular disorders and resulting complications. Dr. Tulio Bertorini and a contributing team of the world’s leading authorities in the field provide the latest tools and strategies for minimizing disability and maximizing quality of life. Effectively treat your patients using the latest management tools and targeted therapeutic strategies. Manage all neuromuscular disorders as well as resulting complications through comprehensive coverage of diagnosis and evaluations, treatments, and outcomes. Apply the multi-disciplinary approach of an expert in clinical neuromuscular care and a team of world-renown contributors. Easily refer to tools for diagnosis, treatment algorithms, and drug tables included throughout the text. |
| axovant gene therapies ltd: Machine Learners Adrian Mackenzie, 2017-11-16 If machine learning transforms the nature of knowledge, does it also transform the practice of critical thought? Machine learning—programming computers to learn from data—has spread across scientific disciplines, media, entertainment, and government. Medical research, autonomous vehicles, credit transaction processing, computer gaming, recommendation systems, finance, surveillance, and robotics use machine learning. Machine learning devices (sometimes understood as scientific models, sometimes as operational algorithms) anchor the field of data science. They have also become mundane mechanisms deeply embedded in a variety of systems and gadgets. In contexts from the everyday to the esoteric, machine learning is said to transform the nature of knowledge. In this book, Adrian Mackenzie investigates whether machine learning also transforms the practice of critical thinking. Mackenzie focuses on machine learners—either humans and machines or human-machine relations—situated among settings, data, and devices. The settings range from fMRI to Facebook; the data anything from cat images to DNA sequences; the devices include neural networks, support vector machines, and decision trees. He examines specific learning algorithms—writing code and writing about code—and develops an archaeology of operations that, following Foucault, views machine learning as a form of knowledge production and a strategy of power. Exploring layers of abstraction, data infrastructures, coding practices, diagrams, mathematical formalisms, and the social organization of machine learning, Mackenzie traces the mostly invisible architecture of one of the central zones of contemporary technological cultures. Mackenzie's account of machine learning locates places in which a sense of agency can take root. His archaeology of the operational formation of machine learning does not unearth the footprint of a strategic monolith but reveals the local tributaries of force that feed into the generalization and plurality of the field. |
| axovant gene therapies ltd: The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia American Psychiatric Association, 2016 The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. |
| axovant gene therapies ltd: Functional Neurobiology of Aging Patrick R. Hof, Charles V. Mobbs, 2001-01-11 Some well-known age-related neurological diseases include Parkinson's disease, Alzheimer's disease, deafness, and blindness. Even more common are the problems of aging which are not due to disease but to more subtle impairments in neurobiological systems, including impairments in vision, memory loss, muscle weakening, and loss of reproductive functions, changes in body weight, and sleeplessness. As the average age of our society increases, diseases of aging continue to become more common, and conditions associated with aging need more attention by doctors and researchers. In 1991, patients over the age of 65 saw their doctors an average of eight times per year. Research funding is provided by the Neuroscience and Neuropsychology of Aging (NNA) Program, which is run by the National Institute on Aging. This book offers a comprehensive overview of all topics related to functional impairments which are related to the aging brain and nervous system. It is organized according to four general functions: movement, senses, memory, and neuroendocrine regulation. Written by the leading researchers in the field, this comprehensive work addresses both impairments associated with diseases and not associated with diseases, making it easier to understand the mechanisms involved. Functional Neurobiology of Aging is an important reference for professionals and students involved in aging research, as well as physicians who need to recognize and understand age-related impairments. - Organized by function, making it easy to find and understand the material - Addresses impairments both associated with diseases and not associated with diseases - Written by leading researchers in the field - Most comprehensive source of information on the neurobiology of aging |
| axovant gene therapies ltd: An Atlas of Alzheimer's Disease M.J. de Leon, 1999-10-15 As the general population ages, the number of elderly patients with mild to severe cognitive impairments can be expected to increase. Improved recognition of the risks for future Alzheimer's Disease (AD), improved characterization of the natural history of AD, and the increased understanding of the neuropathy of AD will lead to early diagnosis and to developing effective treatments. An Atlas of Alzheimer's Disease presents photographs, line drawings, charts, graphs, and text that identify heuristically useful stages of disease progression across behavioral, neuroimaging, and neuropathology research areas. The atlas closely examines the major pathological brain lesions in AD and provides an in-depth view of the neurofibrillary degeneration of AD and beta-amyloid deposits in the brain. It concisely covers current knowledge in the key areas of AD research, including clinical diagnostic features, and explores the clinical, anatomical, and pathological knowledge bases that have shaped our understanding of AD. With its exceptional illustrations and contributions from leading research groups, An Atlas of Alzheimer's Disease provides a deeper understanding of the disease and the importance of early diagnosis and management. |
| axovant gene therapies ltd: Aesthetic Programming Winnie Soon, Geoff Cox, 2020-12-31 The book explores the technical as well as cultural imaginaries of programming from its insides, demonstrating the reflexive practice of aesthetic programming, to understand and question existing technological objects and paradigms. |
| axovant gene therapies ltd: Alzheimer's Disease Amy Borenstein, James Mortimer, 2016-02-16 Alzheimer's Disease: Lifecourse Perspectives on Risk Reduction summarizes the growing body of knowledge on the distribution and causes of Alzheimer's disease (AD) in human populations, providing the reader with knowledge on how we define the disease and what its risk and protective factors are in the context of a life-course approach. At the conclusion of the book, the reader will understand why Alzheimer's disease likely begins at conception, then progresses through early-life and adult risk factors that ultimately impact the balance between pathologic insults in the brain and the ability of the brain to modify disease symptoms. In contrast to edited volumes that may have little cohesion, this book focuses on an integrated life-course approach to the epidemiology of dementia, in particular, Alzheimer's disease. - Reviews the current science surrounding Alzheimer's disease - Provides a primer of foundational knowledge on the disease's epidemiology and biostatistics - Utilizes a life-course approach, providing a novel and integrated view of the evolution of this illness from genes to brain reserve - Uses the 'threshold model'—a theory first described by Dr. Mortimer and widely accepted today—which incorporates the idea of risk factors for the pathology and expression of the disease - Proposes that improving brain health through modifiable behaviors can delay disease onset until a later age - Examines the future of prevention of Alzheimer's disease, a subject of great current interest |
| axovant gene therapies ltd: The Development Factory Gary P. Pisano, 1997 When the pharmaceuticals giant Merck reports promising results for a potential blockbuster drug, the story makes the evening news. Now, at a time when new product development has become critical to success in so many industries, The Development Factory proves that process innovation - not just product innovation - can be the key to competitive edge. In this multiyear study of pharmaceutical and biotechnology firms, Gary Pisano explores the dynamics of superior product and process development in a highly competitive industry that lives and dies by its R&D and depends heavily on rapid time to market. His work reveals that behind the success of many new product introductions lies the development of novel process technologies that provide lower costs, higher quality, and increased flexibility. Pisano challenges the widely held product-process life cycle view of competition, which suggests that industries tend to emphasize either product innovation or process innovation. He also questions the notion that there is a conflict between pursuit of product innovation and pursuit of lower costs, arguing that product development and process development capabilities are complementary. Extending the lessons to a wide variety of manufacturing industries, The Development Factory will guide companies toward unlocking the potential of process development and understanding the patterns of organizational behavior and managerial actions that help create and implement new capabilities over time. |
| axovant gene therapies ltd: Tihany Design Adam Tihany, Nina McCarthy, 1999 Resource added for the Business Management program 101023. |
| axovant gene therapies ltd: Headache and Comorbidities in Childhood and Adolescence Vincenzo Guidetti, Marco A. Arruda, Aynur Ozge, 2017-09-01 This book aims to provide clinicians and other practitioners and professionals with up-to-date information on how to evaluate and manage headaches in children and adolescents, highlighting the most recent recommendations. Unlike in other books on the subject, detailed attention is devoted to the various comorbidities commonly associated with headache, including psychiatric comorbidities such as depression, anxiety, attention deficit hyperactivity disorder, and learning disabilities and medical conditions such as epilepsy, vascular disorders, brain tumors, atopic disease, and obesity. The intimate link between these conditions and headache is explained with a view to enabling the reader to recognize their presence and, on that basis, to institute the most effective pharmacological or non-pharmacological treatment strategy. Moreover, knowledge of the comorbidities associated with headache will help readers to understand more fully the causes of this serious disorder and also its consequences, e.g., for school performance, relationships, and daily activities. The authors are all international experts who care for children with headache or the other described disorders. |
| axovant gene therapies ltd: Late-Life Depression Steven P. Roose M.D., Harold A. Sackeim, 2004-07-15 We live in an aging world. Illnesses that are prevalent and cause significant morbidity and mortality in older people will consume an increasing share of health care resources. One such illness is depression. This illness has a particularly devastating impact in the elderly because it is often undiagnosed or inadequately treated. Depression not only has a profound impact on quality of life but it is associated with an increased risk of mortality from suicide and vascular disease. In fact for every medical illness studied, e.g. heart disease, diabetes, cancer, individuals who are depressed have a worse prognosis. Research has illuminated the physiological and behavioral effects of depression that accounts for these poor outcomes. The deleterious relationship between depression and other illnesses has changed the concept of late-life depression from a psychiatric disorder that is diagnosed and treated by a psychiatrist to a common and serious disorder that is the responsibility of all physicians who care for patients over the age of 60. This is the first volume devoted to the epidemiology, phenomenology, psychobiology, treatment and consequences of late-life depression. Although much has been written about depressive disorders, the focus has been primarily on the illness as experienced in younger adults. The effects of aging on the brain, the physiological and behavioral consequences of recurrent depression, and the impact of other diseases common in the elderly, make late-life depression a distinct entity. There is a compelling need for a separate research program, specialized treatments, and a book dedicated to this disorder. This book will be invaluable to psychiatrists, gerontologists, clinical psychologists, social workers, students, trainees, and others who care for individuals over the age of sixty. |
| axovant gene therapies ltd: Making India Great Aparna Pande, 2020-08-13 India will be the world's most populous country by 2024 and its third largest economy by 2028. But the size of our population and a sense of historical greatness alone are insufficient to guarantee we will fulfil our ambition to become a global power. Our approach to realize this vision needs more than just planning for economic growth. It requires a shift in attitudes. In Making India Great, Aparna Pande examines the challenges we face in the areas of social, economic, military and foreign policy and strategy. She points to the dichotomy that lies at the heart of the nation: our belief in becoming a global power and the reluctance to implement policies and take actions that would help us achieve that goal. The New India holds all the promise of greatness many of its citizens dream of. Can it become a reality? The book delves into this question. |
| axovant gene therapies ltd: Executing Practices Helen Pritchard, Eric Snodgrass, Magda Tyżlik-Carver, 2018-12 From the contestable politics of emoji modifier mechanisms and micro-temporalities of computational processes to genomic exploitation and the curating of digital content, Executing Practices highlights a range of ways in which execution emerges and how it participates within networked forms of liveliness. |
| axovant gene therapies ltd: Mental Health and Illness of the Elderly Helen Chiu, Kenneth Shulman, 2017-08-22 This book consolidates current knowledge in the field and discusses psychiatric disorders among the elderly, while bridging the gap between clinical practice and the socio-cultural contexts. The book is particularly important in the face of rapidly changing conditions globally and challenges such as migration, war and violence, diminishing physical health due to ageing and their impact on the mental health of elderly. Longevity is a great gift of medical sciences and modern health care and since the benefit of longevity comes with specific mental health issues of the elderly, this book responds to the heightened need to understand and address the mental health challenges of the elderly. |
| axovant gene therapies ltd: Patents Act 1990 (Australia) (2018 Edition) The Law The Law Library, 2018-05-31 Patents Act 1990 (Australia) (2018 Edition) The Law Library presents the complete text of the Patents Act 1990 (Australia) (2018 Edition). Updated as of May 15, 2018 This book contains: - The complete text of the Patents Act 1990 (Australia) (2018 Edition) - A table of contents with the page number of each section |
| axovant gene therapies ltd: Translational Research in Cancer Sivapatham Sundaresan, Yeun-Hwa Gu, 2021 |
| axovant gene therapies ltd: Mallard Fillmore-- Bruce Tinsley, 1995 Mallard Fillmore lampoons everything from political correctness to Phil, Oprah, and Geraldo to our government's insatiable appetite for spending our money. His marvelous supporting cast includes wickedly wonderful cariacatures of everyone who's anyone, from Hollywood to D.C. to Arkansas. |
| axovant gene therapies ltd: WHO manual for surveillance of human transmissible spongiform encephalopathies including variant Creutzfeldt-Jakob disease , 2003 |
| axovant gene therapies ltd.: The Venture Alchemists Rob Lalka, 2024-05-14 We once idolized tech entrepreneurs for creating innovations that seemed like modern miracles. Yet our faith has been shattered. We now blame them for spreading lies, breaking laws, and causing chaos. Yesterday’s Silicon Valley darlings have become today’s Big Tech villains. Which is it? Are they superheroes or scoundrels? Or is it more complicated, some blend of both? In The Venture Alchemists, Rob Lalka demystifies how tech entrepreneurs built empires that made trillions. Meta started as a cruel Halloween prank, Alphabet began as a master’s thesis that warned against corporate deception, and Palantir came from a campus controversy over hateful speech. These largely forgotten origin stories show how ordinary fears and youthful ambitions shaped their ventures—making each tech tale relatable, both wonderfully and tragically human. Readers learn about the adversities tech entrepreneurs overcame, the troubling tradeoffs they made, and the tremendous power they now wield. Using leaked documents and previously unpublished archival material, Lalka takes readers inside Big Tech’s worst exploitations and abuses, alongside many good intentions and moral compromises. But this story remains unfinished, and The Venture Alchemists ultimately offers hope from the people who, decades ago, warned about the risks of the emerging Internet. Their insights illuminate a path toward more responsible innovations, so that technologies aren’t dangerous weapons but valuable tools that ensure progress, improve society, and enhance our daily lives. |
| axovant gene therapies ltd.: The Behavioral Neurology of Dementia Bruce L. Miller, Bradley F. Boeve, 2016-11-17 Distils the most valuable discoveries in dementia research into clear, insightful chapters written by international experts. |
| axovant gene therapies ltd.: Dementia with Lewy Bodies John O'Brien, David Ames, Ian McKeith, Edmond Chiu, 2005-11-29 Filling a noticeable gap in the market for a new text solely focused on Dementia with Lewy Bodies, this book discusses cutting-edge topics covering the condition from diagnosis to management, as well as what is known about the neurobiological changes involved. With huge progress having been made over the last decade in terms of the disorder |
| axovant gene therapies ltd.: Parkinson's Disease Jason S. Hawley, Melissa J. Armstrong, William J. Weiner, 2014-02 Parkinson's Disease: Improving Patient Care is a clinically-focused text for healthcare professionals involved in everyday management of Parkinson's disease patients. Concise chapters and abundant tables make it easy to read or use as a handy reference. |
| axovant gene therapies ltd.: Coding Literacy Annette Vee, 2017-07-28 How the theoretical tools of literacy help us understand programming in its historical, social and conceptual contexts. The message from educators, the tech community, and even politicians is clear: everyone should learn to code. To emphasize the universality and importance of computer programming, promoters of coding for everyone often invoke the concept of “literacy,” drawing parallels between reading and writing code and reading and writing text. In this book, Annette Vee examines the coding-as-literacy analogy and argues that it can be an apt rhetorical frame. The theoretical tools of literacy help us understand programming beyond a technical level, and in its historical, social, and conceptual contexts. Viewing programming from the perspective of literacy and literacy from the perspective of programming, she argues, shifts our understandings of both. Computer programming becomes part of an array of communication skills important in everyday life, and literacy, augmented by programming, becomes more capacious. Vee examines the ways that programming is linked with literacy in coding literacy campaigns, considering the ideologies that accompany this coupling, and she looks at how both writing and programming encode and distribute information. She explores historical parallels between writing and programming, using the evolution of mass textual literacy to shed light on the trajectory of code from military and government infrastructure to large-scale businesses to personal use. Writing and coding were institutionalized, domesticated, and then established as a basis for literacy. Just as societies demonstrated a “literate mentality” regardless of the literate status of individuals, Vee argues, a “computational mentality” is now emerging even though coding is still a specialized skill. |
| axovant gene therapies ltd.: Spotify Teardown Maria Eriksson, Rasmus Fleischer, Anna Johansson, Pelle Snickars, Patrick Vonderau, 2019-02-19 An innovative investigation of the inner workings of Spotify that traces the transformation of audio files into streamed experience. Spotify provides a streaming service that has been welcomed as disrupting the world of music. Yet such disruption always comes at a price. Spotify Teardown contests the tired claim that digital culture thrives on disruption. Borrowing the notion of “teardown” from reverse-engineering processes, in this book a team of five researchers have playfully disassembled Spotify's product and the way it is commonly understood. Spotify has been hailed as the solution to illicit downloading, but it began as a partly illicit enterprise that grew out of the Swedish file-sharing community. Spotify was originally praised as an innovative digital platform but increasingly resembles a media company in need of regulation, raising questions about the ways in which such cultural content as songs, books, and films are now typically made available online. Spotify Teardown combines interviews, participant observations, and other analyses of Spotify's “front end” with experimental, covert investigations of its “back end.” The authors engaged in a series of interventions, which include establishing a record label for research purposes, intercepting network traffic with packet sniffers, and web-scraping corporate materials. The authors' innovative digital methods earned them a stern letter from Spotify accusing them of violating its terms of use; the company later threatened their research funding. Thus, the book itself became an intervention into the ethics and legal frameworks of corporate behavior. |
| axovant gene therapies ltd.: Neurodegeneration Dennis Dickson, Roy O. Weller, 2011-11-07 Most textbooks on neurodegenerative disorders have used a classification scheme based upon either clinical syndromes or anatomical distribution of the pathology. In contrast, this book looks to the future and uses a classification based upon molecular mechanisms, rather than clinical or anatomical boundaries. Major advances in molecular genetics and the application of biochemical and immunocytochemical techniques to neurodegenerative disorders have generated this new approach. Throughout most of the current volume, diseases are clustered according to the proteins that accumulate within cells (e.g. tau, α-synuclein and TDP-43) and in the extracellular compartments (e.g. β-amyloid and prion proteins) or according to a shared pathogenetic mechanism, such as trinucleotide repeats, that are a feature of specific genetic disorders. Chapters throughout the book conform to a standard lay-out for ease of access by the reader and are written by a panel of International Experts Since the first edition of this book, major advances have been made in the discovery of common molecular mechanisms between many neurodegenerative diseases most notably in the frontotemporal lobar degenerations (FTLD) and motor neuron disease or amyotrophic lateral sclerosis. This book will be essential reading for clinicians, neuropathologists and basic neuroscientists who require the firm up-to-date knowledge of mechanisms, diagnostic pathology and genetics of Neurodegenerative diseases that is required for progress in therapy and management. |
| axovant gene therapies ltd.: Disorders of Movement Davide Martino, Alberto J. Espay, Alfonso Fasano, Francesca Morgante, 2015-12-17 This concise but comprehensive book will help interested readers in the health care professions to navigate their way through the jungle of movement disorders, including the potentially complex differential diagnosis and management. The different disorders are discussed in individual sections that explain how to examine the patient and recognize the disorder from its basic phenomenology, how to confirm a diagnosis, how to distinguish a particular disorder from related conditions, and how to treat each disorder effectively. The book makes liberal use of diagrams, algorithms, tables, summary boxes, and illustrations to facilitate solution of clinical problems at the bedside and to solidify previously learned clinical and therapeutic concepts. It will be of interest to a broad audience of health professionals, scientists, and medical students. |
| axovant gene therapies ltd.: PDQ Statistics Geoffrey R. Norman, David L. Streiner, PhD, 2003-01-01 The third edition of PDQ Statistics provides an overview of all major statistical methods, giving the reader a good understanding of statistics and how they are used in research articles. It covers the major categories – variable and descriptive statistics, parametric statistics, non-parametric statistics, and multivariate statistics. The explanations are clear, succinct, and loaded with practical examples. |
| axovant gene therapies ltd.: Encyclopedia of Psychopharmacology Ian Stolerman, 2010-07-31 Here is a broad overview of the central topics and issues in psychopharmacology, biological psychiatry and behavioral neurosciences, with information about developments in the field, including novel drugs and technologies. The more than 2000 entries are written by leading experts in pharmacology and psychiatry and comprise in-depth essays, illustrated with full-color figures, and are presented in a lucid style. |
| axovant gene therapies ltd.: Free Energy Calculations Christophe Chipot, Andrew Pohorille, 2007-01-08 Free energy constitutes the most important thermodynamic quantity to understand how chemical species recognize each other, associate or react. Examples of problems in which knowledge of the underlying free energy behaviour is required, include conformational equilibria and molecular association, partitioning between immiscible liquids, receptor-drug interaction, protein-protein and protein-DNA association, and protein stability. This volume sets out to present a coherent and comprehensive account of the concepts that underlie different approaches devised for the determination of free energies. The reader will gain the necessary insight into the theoretical and computational foundations of the subject and will be presented with relevant applications from molecular-level modelling and simulations of chemical and biological systems. Both formally accurate and approximate methods are covered using both classical and quantum mechanical descriptions. A central theme of the book is that the wide variety of free energy calculation techniques available today can be understood as different implementations of a few basic principles. The book is aimed at a broad readership of graduate students and researchers having a background in chemistry, physics, engineering and physical biology. |
| axovant gene therapies ltd.: Epilepsy and the Interictal State Erik K. St Louis, David M. Ficker, Terence J. O'Brien, 2015-03-02 Epilepsy care traditionally focuses on seizures, yet for most epilepsy sufferers, other interictal factors such as mood, cognitive abilities, and treatment adverse effects most influence how they feel and function day to day. Epilepsy and the Interictal State is a practical and comprehensive text that covers quality of life issues, cognition and therapy, adverse effects of epilepsy treatments, mood state and psychiatric co-morbidity and general health aspects of epilepsy. Each chapter employs a standard structure providing background, epidemiology, pathophysiology, etiology, diagnosis, treatment, prognosis and further practical advice. From an international team of expert editors and contributors, Epilepsy and the Interictal State is a valuable resource for specialist epileptologists and neurologists, as well as for neurosurgeons, neurology nurses, psychiatrists, family physicians and general practitioners. |
| axovant gene therapies ltd.: Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders Adeboye Adejare, 2025-09-01 Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease, 2nd Edition examines the drug discovery process for neurodegenerative diseases by focusing specifically on Alzheimer's Disease and illustrating the paradigm necessary to ensure future research and treatment success. The new edition of this book is updated with the most recent developments around the therapeutic strategies for drug discovery like amyloid hypothesis, tau, apo E, insulin, and others. It also includes a new chapter on drug delivery to the brain. The content covers diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more to provide a holistic approach to the discovery, development, and treatment of Alzheimer's Disease. Through its coverage of the latest research in targeted drug design, preclinical studies, and mouse and rat models, the book is a must-have resource for all pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers working in this area. Pharmaceutical researchers will benefit from the updated coverage on therapeutic approaches to neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, multiple sclerosis, frontotemporal disorder, Huntington's diseases and many more. Patients and advocacy groups can also benefit from the overview of current treatment options and the scientific progress in the field.• Covers Monoclonal Antibodies approaches• Provides a compilation of chemical considerations required in drug discovery for thetreatment of neurodegenerative disorders• Explores how in vitro and in vivo models translate to human physiology |
| axovant gene therapies ltd.: Restless Legs Syndrome/Willis Ekbom Disease Mauro Manconi, Diego García-Borreguero, 2017-05-07 Due to the fact that Restless Legs Syndrome/Willis-Ekbom Disease is usually a chronic condition, this book aims to provide physicians with the necessary tools for the long-term management of patients with RLS. The first part of the book addresses the various comorbidities and long-term consequences of RLS on life quality, sleep, cognitive, psychiatric and cardiovascular systems, while the second part focuses on the management of long-term treatment and the drug-induced complications in primary RLS and in special populations. Written by experts in the field, this practical resource offers a high-quality, long-term management of RLS for neurologists, sleep clinicians, pulmonologists and other healthcare professionals. |
| axovant gene therapies ltd.: Brain Banking , 2018-02-27 Brain Banking, Volume 150, serves as the only book on the market offering comprehensive coverage of the functional realities of brain banking. It focuses on brain donor recruitment strategies, brain bank networks, ethical issues, brain dissection/tissue processing/tissue dissemination, neuropathological diagnosis, brain donor data, and techniques in brain tissue analysis. In accordance with massive initiatives, such as BRAIN and the EU Human Brain Project, abnormalities and potential therapeutic targets of neurological and psychiatric disorders need to be validated in human brain tissue, thus requiring substantial numbers of well characterized human brains of high tissue quality with neurological and psychiatric diseases. - Offers comprehensive coverage of the functional realities of brain banking, with a focus on brain donor recruitment strategies, brain bank networks, ethical issues, and more - Serves as a valuable resource for staff in existing brain banks by highlighting best practices - Enhances the sharing of expertise between existing banks and highlights a range of techniques applicable to banked tissue for neuroscience researchers - Authored by leaders from brain banks around the globe – the broadest, most expert coverage available |
| axovant gene therapies ltd.: Clinical Epileptology Nyla Shelton, 2021-11-16 Epileptology is a specialization under neurology which deals with the treatment of epilepsy. It is the study of epileptic seizures and seizure disorders, and anticonvulsants. Epilepsy is a group of neurological disorders. Recurrent epileptic seizures are the main signs of epilepsy. These are episodes that can vary from long periods of vigorous shaking to short and nearly undetectable periods. They are caused by abnormal electrical activity in the brain. Generally, an epileptologist is not required for the treatment of all seizure disorders and is consulted only if the seizures do not stop, even after the treatment from a regular neurologist. Epileptic seizures occur due to excessive and abnormal activity in the brain. Different approaches, evaluations, methodologies and advanced studies on epileptology have been included in this book. It strives to provide a fair idea about this discipline and to help develop a better understanding of this field. This book will provide comprehensive knowledge to the readers. |
| axovant gene therapies ltd.: Biomarkers in Psychiatry Judith Pratt, Jeremy Hall, 2019-01-05 This volume addresses one of the Holy Grails in Psychiatry, namely the evidence for and potential to adopt ‘Biomarkers’ for prevention, diagnosis, and treatment responses in mental health conditions. It meshes together state of the art research from international renowned pre-clinical and clinical scientists to illustrate how the fields of anxiety disorders, depression, psychotic disorders, and autism spectrum disorder have advanced in recent years. |
| axovant gene therapies ltd.: Education about Mental Health and Illness Marc H.M. Hermans, Tan Chay-Hoon, Edmond Pi, 2019-05-24 This book highlights the best educational practices for the professionals dealing with mental health and illness. While attempting an overall review of the current state-of-the-art in psychiatry education, the book focuses on recent developments and controversies in undergraduate and postgraduate psychiatric education around the globe. |
| axovant gene therapies ltd.: Alzheimer's Disease Drug Development Jeffrey Cummings, Jefferson Kinney, Howard Fillit, 2022-03-31 Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models. |
| axovant gene therapies ltd.: Cerebrospinal Fluid Biomarkers Charlotte E. Teunissen, Henrik Zetterberg, 2022-05-19 This volume covers the latest methods used in clinical neurochemistry laboratories for both clinical practice and research. Chapters in this book discuss topics such as techniques for cerebrospinal fluid (CSF) collection, pre-analytical processing, and basic CSF analysis; an examination of biomarkers including ELISA and automated immunochemical assays for amyloid and tau markers for Alzheimer’s disease; the analysis of neurofilaments by digital ELISA; and an example of successful novel immunoassay development. In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Cutting-edge and thorough, Cerebrospinal Fluid Biomarkers is a valuable resource for clinicians and researchers to use in CSF labs and CSF courses. |
| axovant gene therapies ltd.: Neuromuscular Disorders: Management and Treatment E-Book Tulio E. Bertorini, 2010-09-08 Neuromuscular Disorders presents a multi-disciplinary approach to the management and therapeutic treatment of the full range of neuromuscular disorders and resulting complications. Dr. Tulio Bertorini and a contributing team of the world’s leading authorities in the field provide the latest tools and strategies for minimizing disability and maximizing quality of life. Effectively treat your patients using the latest management tools and targeted therapeutic strategies. Manage all neuromuscular disorders as well as resulting complications through comprehensive coverage of diagnosis and evaluations, treatments, and outcomes. Apply the multi-disciplinary approach of an expert in clinical neuromuscular care and a team of world-renown contributors. Easily refer to tools for diagnosis, treatment algorithms, and drug tables included throughout the text. |
| axovant gene therapies ltd.: Machine Learners Adrian Mackenzie, 2017-11-16 If machine learning transforms the nature of knowledge, does it also transform the practice of critical thought? Machine learning—programming computers to learn from data—has spread across scientific disciplines, media, entertainment, and government. Medical research, autonomous vehicles, credit transaction processing, computer gaming, recommendation systems, finance, surveillance, and robotics use machine learning. Machine learning devices (sometimes understood as scientific models, sometimes as operational algorithms) anchor the field of data science. They have also become mundane mechanisms deeply embedded in a variety of systems and gadgets. In contexts from the everyday to the esoteric, machine learning is said to transform the nature of knowledge. In this book, Adrian Mackenzie investigates whether machine learning also transforms the practice of critical thinking. Mackenzie focuses on machine learners—either humans and machines or human-machine relations—situated among settings, data, and devices. The settings range from fMRI to Facebook; the data anything from cat images to DNA sequences; the devices include neural networks, support vector machines, and decision trees. He examines specific learning algorithms—writing code and writing about code—and develops an archaeology of operations that, following Foucault, views machine learning as a form of knowledge production and a strategy of power. Exploring layers of abstraction, data infrastructures, coding practices, diagrams, mathematical formalisms, and the social organization of machine learning, Mackenzie traces the mostly invisible architecture of one of the central zones of contemporary technological cultures. Mackenzie's account of machine learning locates places in which a sense of agency can take root. His archaeology of the operational formation of machine learning does not unearth the footprint of a strategic monolith but reveals the local tributaries of force that feed into the generalization and plurality of the field. |
| axovant gene therapies ltd.: The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia American Psychiatric Association, 2016 The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. |
| axovant gene therapies ltd.: Functional Neurobiology of Aging Patrick R. Hof, Charles V. Mobbs, 2001-01-11 Some well-known age-related neurological diseases include Parkinson's disease, Alzheimer's disease, deafness, and blindness. Even more common are the problems of aging which are not due to disease but to more subtle impairments in neurobiological systems, including impairments in vision, memory loss, muscle weakening, and loss of reproductive functions, changes in body weight, and sleeplessness. As the average age of our society increases, diseases of aging continue to become more common, and conditions associated with aging need more attention by doctors and researchers. In 1991, patients over the age of 65 saw their doctors an average of eight times per year. Research funding is provided by the Neuroscience and Neuropsychology of Aging (NNA) Program, which is run by the National Institute on Aging. This book offers a comprehensive overview of all topics related to functional impairments which are related to the aging brain and nervous system. It is organized according to four general functions: movement, senses, memory, and neuroendocrine regulation. Written by the leading researchers in the field, this comprehensive work addresses both impairments associated with diseases and not associated with diseases, making it easier to understand the mechanisms involved. Functional Neurobiology of Aging is an important reference for professionals and students involved in aging research, as well as physicians who need to recognize and understand age-related impairments. - Organized by function, making it easy to find and understand the material - Addresses impairments both associated with diseases and not associated with diseases - Written by leading researchers in the field - Most comprehensive source of information on the neurobiology of aging |
| axovant gene therapies ltd.: An Atlas of Alzheimer's Disease M.J. de Leon, 1999-10-15 As the general population ages, the number of elderly patients with mild to severe cognitive impairments can be expected to increase. Improved recognition of the risks for future Alzheimer's Disease (AD), improved characterization of the natural history of AD, and the increased understanding of the neuropathy of AD will lead to early diagnosis and to developing effective treatments. An Atlas of Alzheimer's Disease presents photographs, line drawings, charts, graphs, and text that identify heuristically useful stages of disease progression across behavioral, neuroimaging, and neuropathology research areas. The atlas closely examines the major pathological brain lesions in AD and provides an in-depth view of the neurofibrillary degeneration of AD and beta-amyloid deposits in the brain. It concisely covers current knowledge in the key areas of AD research, including clinical diagnostic features, and explores the clinical, anatomical, and pathological knowledge bases that have shaped our understanding of AD. With its exceptional illustrations and contributions from leading research groups, An Atlas of Alzheimer's Disease provides a deeper understanding of the disease and the importance of early diagnosis and management. |
| axovant gene therapies ltd.: Aesthetic Programming Winnie Soon, Geoff Cox, 2020-12-31 The book explores the technical as well as cultural imaginaries of programming from its insides, demonstrating the reflexive practice of aesthetic programming, to understand and question existing technological objects and paradigms. |
| axovant gene therapies ltd.: Alzheimer's Disease Amy Borenstein, James Mortimer, 2016-02-16 Alzheimer's Disease: Lifecourse Perspectives on Risk Reduction summarizes the growing body of knowledge on the distribution and causes of Alzheimer's disease (AD) in human populations, providing the reader with knowledge on how we define the disease and what its risk and protective factors are in the context of a life-course approach. At the conclusion of the book, the reader will understand why Alzheimer's disease likely begins at conception, then progresses through early-life and adult risk factors that ultimately impact the balance between pathologic insults in the brain and the ability of the brain to modify disease symptoms. In contrast to edited volumes that may have little cohesion, this book focuses on an integrated life-course approach to the epidemiology of dementia, in particular, Alzheimer's disease. - Reviews the current science surrounding Alzheimer's disease - Provides a primer of foundational knowledge on the disease's epidemiology and biostatistics - Utilizes a life-course approach, providing a novel and integrated view of the evolution of this illness from genes to brain reserve - Uses the 'threshold model'—a theory first described by Dr. Mortimer and widely accepted today—which incorporates the idea of risk factors for the pathology and expression of the disease - Proposes that improving brain health through modifiable behaviors can delay disease onset until a later age - Examines the future of prevention of Alzheimer's disease, a subject of great current interest |
| axovant gene therapies ltd.: The Development Factory Gary P. Pisano, 1997 When the pharmaceuticals giant Merck reports promising results for a potential blockbuster drug, the story makes the evening news. Now, at a time when new product development has become critical to success in so many industries, The Development Factory proves that process innovation - not just product innovation - can be the key to competitive edge. In this multiyear study of pharmaceutical and biotechnology firms, Gary Pisano explores the dynamics of superior product and process development in a highly competitive industry that lives and dies by its R&D and depends heavily on rapid time to market. His work reveals that behind the success of many new product introductions lies the development of novel process technologies that provide lower costs, higher quality, and increased flexibility. Pisano challenges the widely held product-process life cycle view of competition, which suggests that industries tend to emphasize either product innovation or process innovation. He also questions the notion that there is a conflict between pursuit of product innovation and pursuit of lower costs, arguing that product development and process development capabilities are complementary. Extending the lessons to a wide variety of manufacturing industries, The Development Factory will guide companies toward unlocking the potential of process development and understanding the patterns of organizational behavior and managerial actions that help create and implement new capabilities over time. |
| axovant gene therapies ltd.: Tihany Design Adam Tihany, Nina McCarthy, 1999 Resource added for the Business Management program 101023. |
| axovant gene therapies ltd.: Headache and Comorbidities in Childhood and Adolescence Vincenzo Guidetti, Marco A. Arruda, Aynur Ozge, 2017-09-01 This book aims to provide clinicians and other practitioners and professionals with up-to-date information on how to evaluate and manage headaches in children and adolescents, highlighting the most recent recommendations. Unlike in other books on the subject, detailed attention is devoted to the various comorbidities commonly associated with headache, including psychiatric comorbidities such as depression, anxiety, attention deficit hyperactivity disorder, and learning disabilities and medical conditions such as epilepsy, vascular disorders, brain tumors, atopic disease, and obesity. The intimate link between these conditions and headache is explained with a view to enabling the reader to recognize their presence and, on that basis, to institute the most effective pharmacological or non-pharmacological treatment strategy. Moreover, knowledge of the comorbidities associated with headache will help readers to understand more fully the causes of this serious disorder and also its consequences, e.g., for school performance, relationships, and daily activities. The authors are all international experts who care for children with headache or the other described disorders. |
| axovant gene therapies ltd.: Late-Life Depression Steven P. Roose M.D., Harold A. Sackeim, 2004-07-15 We live in an aging world. Illnesses that are prevalent and cause significant morbidity and mortality in older people will consume an increasing share of health care resources. One such illness is depression. This illness has a particularly devastating impact in the elderly because it is often undiagnosed or inadequately treated. Depression not only has a profound impact on quality of life but it is associated with an increased risk of mortality from suicide and vascular disease. In fact for every medical illness studied, e.g. heart disease, diabetes, cancer, individuals who are depressed have a worse prognosis. Research has illuminated the physiological and behavioral effects of depression that accounts for these poor outcomes. The deleterious relationship between depression and other illnesses has changed the concept of late-life depression from a psychiatric disorder that is diagnosed and treated by a psychiatrist to a common and serious disorder that is the responsibility of all physicians who care for patients over the age of 60. This is the first volume devoted to the epidemiology, phenomenology, psychobiology, treatment and consequences of late-life depression. Although much has been written about depressive disorders, the focus has been primarily on the illness as experienced in younger adults. The effects of aging on the brain, the physiological and behavioral consequences of recurrent depression, and the impact of other diseases common in the elderly, make late-life depression a distinct entity. There is a compelling need for a separate research program, specialized treatments, and a book dedicated to this disorder. This book will be invaluable to psychiatrists, gerontologists, clinical psychologists, social workers, students, trainees, and others who care for individuals over the age of sixty. |
| axovant gene therapies ltd.: Making India Great Aparna Pande, 2020-08-13 India will be the world's most populous country by 2024 and its third largest economy by 2028. But the size of our population and a sense of historical greatness alone are insufficient to guarantee we will fulfil our ambition to become a global power. Our approach to realize this vision needs more than just planning for economic growth. It requires a shift in attitudes. In Making India Great, Aparna Pande examines the challenges we face in the areas of social, economic, military and foreign policy and strategy. She points to the dichotomy that lies at the heart of the nation: our belief in becoming a global power and the reluctance to implement policies and take actions that would help us achieve that goal. The New India holds all the promise of greatness many of its citizens dream of. Can it become a reality? The book delves into this question. |
| axovant gene therapies ltd.: Executing Practices Helen Pritchard, Eric Snodgrass, Magda Tyżlik-Carver, 2018-12 From the contestable politics of emoji modifier mechanisms and micro-temporalities of computational processes to genomic exploitation and the curating of digital content, Executing Practices highlights a range of ways in which execution emerges and how it participates within networked forms of liveliness. |
| axovant gene therapies ltd.: Mental Health and Illness of the Elderly Helen Chiu, Kenneth Shulman, 2017-08-22 This book consolidates current knowledge in the field and discusses psychiatric disorders among the elderly, while bridging the gap between clinical practice and the socio-cultural contexts. The book is particularly important in the face of rapidly changing conditions globally and challenges such as migration, war and violence, diminishing physical health due to ageing and their impact on the mental health of elderly. Longevity is a great gift of medical sciences and modern health care and since the benefit of longevity comes with specific mental health issues of the elderly, this book responds to the heightened need to understand and address the mental health challenges of the elderly. |
| axovant gene therapies ltd.: Patents Act 1990 (Australia) (2018 Edition) The Law The Law Library, 2018-05-31 Patents Act 1990 (Australia) (2018 Edition) The Law Library presents the complete text of the Patents Act 1990 (Australia) (2018 Edition). Updated as of May 15, 2018 This book contains: - The complete text of the Patents Act 1990 (Australia) (2018 Edition) - A table of contents with the page number of each section |
| axovant gene therapies ltd.: Translational Research in Cancer Sivapatham Sundaresan, Yeun-Hwa Gu, 2021 |
| axovant gene therapies ltd.: Mallard Fillmore-- Bruce Tinsley, 1995 Mallard Fillmore lampoons everything from political correctness to Phil, Oprah, and Geraldo to our government's insatiable appetite for spending our money. His marvelous supporting cast includes wickedly wonderful cariacatures of everyone who's anyone, from Hollywood to D.C. to Arkansas. |
| axovant gene therapies ltd.: WHO manual for surveillance of human transmissible spongiform encephalopathies including variant Creutzfeldt-Jakob disease , 2003 |
Sio Gene Therapies - Wikipedia
Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies) was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The …
Sio Gene Therapies comes to the end of its rocky road
3 days ago · Sio Gene Therapies' litany of clinical disappointments over the last few years has finally led to the demise of the biotech, formerly known as Axovant and one of the 'vant' …
Sio Gene Therapies to dissolve after years of setbacks
Dec 15, 2022 · The company rebranded as Axovant Gene Therapies in 2019 and spun out its small molecule research into a company called Arvelle Therapeutics. Shares in the company …
Axovant Gene Therapies Announces Name Change to Sio Gene …
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for …
Axovant trumpets new clinical data after gene therapy pivot
Mar 11, 2019 · Axovant has a pair of clinical readouts from its switch into gene therapy after failed endeavours in Alzheimer’s disease—and the initial data look encouraging.
Axovant Changes Name to Sio Gene Therapies, Adding to List ... - BioSpace
Nov 10, 2020 · Clinical-stage gene therapy company Axovant Gene Therapies is changing its name to Sio Gene Therapies, a move that will likely further distance the company from …
Sio Gene Therapies (formerly Axovant) - F6S
Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating …
Axovant axes dementia drug after disastrous trial results
1 day ago · Axovant has axed development of its key dementia drug intepirdine after results suggested it actually worsened symptoms compared with placebo.
Axovant: An Interesting Turnaround Story With A Promising …
Feb 21, 2019 · Axovant Sciences has transformed itself into a gene therapy company, now renamed as Axovant Gene Therapies, with at least six ongoing programs. Shares seem to …
After setbacks, a gene therapy company mulls a sale
Apr 28, 2022 · Sio Gene Therapies, formerly known as Axovant, said it's focused on conserving cash, and has decided to significantly reduce its workforce and terminate licensing …
Axovant Gene Therapies Announces Name Change to Sio Gene …
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for …
Potential Parkinson's Therapy, AXO-Lenti-PD, Under License by Axovant
Jun 8, 2018 · Axovant Sciences licensed the exclusive worldwide rights from Oxford BioMedica to develop and market AXO-Lenti-PD, a gene therapy candidate for Parkinson’s disease.
Axovant Gene Therapies Announces Name Change to Sio Gene
Nov 10, 2020 · Axovant Gene Therapies Ltd., a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases, announced it will change its name …
Axovant Gene Therapies Announces FDA Clearance of IND for
Nov 9, 2020 · AXO-AAV-GM2 is the first investigational gene therapy to achieve IND clearance for Tay-Sachs and Sandhoff diseases. The Company received a letter from the FDA...
Axovant CEO David Hung quits after Alzheimer's drug failure
2 days ago · Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s – and the fall-out is still being felt, with CEO David Hung deciding to walk out.
Fast track for dementia drug good news for Axovant and new CEO
Jun 9, 2025 · Axovant has gained FDA fast track designation for its pipeline drug nelotanserin, a treatment for visual hallucinations suffered by people with dementia with Lewy bodies (DLB).
Axovant pushes on with Parkinson's gene therapy, despite …
Oct 7, 2020 · Axovant has said it plans to continue developing its Parkinson’s Disease gene therapy after reporting supportive data from a small cohort of patients from a phase 2 trial.
Axovant axes neuroscience drug, focuses on gene therapies
4 days ago · Swiss biotech Axovant started the year badly, dropping its Alzheimer’s drug intepirdine after it failed in a trial, and it has ended with another flop from a neuroscience drug, …
FDA clears IND application for Tay-Sachs gene therapy
Nov 9, 2020 · The Axovant therapy, AXO-AAV-GM2, is the first investigational gene therapy to achieve IND clearance for Tay-Sachs and Sandhoff. The clinical hold was in place to resolve …
TanganSakti99 - Situs Slot Online Gacor 2025 dengan Bonus
TanganSakti99 adalah platform slot online gacor 2025 terpercaya yang juga menyediakan voucher game digital terlengkap. Mainkan slot RTP tinggi dan klaim bonus menarik setiap hari!
Sio Gene Therapies - Wikipedia
Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies) was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The …
Sio Gene Therapies comes to the end of its rocky road
3 days ago · Sio Gene Therapies' litany of clinical disappointments over the last few years has finally led to the demise of the biotech, formerly known as Axovant and one of the 'vant' …
Sio Gene Therapies to dissolve after years of setbacks
Dec 15, 2022 · The company rebranded as Axovant Gene Therapies in 2019 and spun out its small molecule research into a company called Arvelle Therapeutics. Shares in the company …
Axovant Gene Therapies Announces Name Change to Sio Gene …
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for …
Axovant trumpets new clinical data after gene therapy pivot
Mar 11, 2019 · Axovant has a pair of clinical readouts from its switch into gene therapy after failed endeavours in Alzheimer’s disease—and the initial data look encouraging.
Axovant Changes Name to Sio Gene Therapies, Adding to List ... - BioSpace
Nov 10, 2020 · Clinical-stage gene therapy company Axovant Gene Therapies is changing its name to Sio Gene Therapies, a move that will likely further distance the company from …
Sio Gene Therapies (formerly Axovant) - F6S
Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating …
Axovant axes dementia drug after disastrous trial results
1 day ago · Axovant has axed development of its key dementia drug intepirdine after results suggested it actually worsened symptoms compared with placebo.
Axovant: An Interesting Turnaround Story With A Promising …
Feb 21, 2019 · Axovant Sciences has transformed itself into a gene therapy company, now renamed as Axovant Gene Therapies, with at least six ongoing programs. Shares seem to …
After setbacks, a gene therapy company mulls a sale
Apr 28, 2022 · Sio Gene Therapies, formerly known as Axovant, said it's focused on conserving cash, and has decided to significantly reduce its workforce and terminate licensing …
Axovant Gene Therapies Announces Name Change to Sio Gene …
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for …
Potential Parkinson's Therapy, AXO-Lenti-PD, Under License by Axovant
Jun 8, 2018 · Axovant Sciences licensed the exclusive worldwide rights from Oxford BioMedica to develop and market AXO-Lenti-PD, a gene therapy candidate for Parkinson’s disease.
Axovant Gene Therapies Announces Name Change to Sio Gene
Nov 10, 2020 · Axovant Gene Therapies Ltd., a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases, announced it will change its name …
Axovant Gene Therapies Announces FDA Clearance of IND for
Nov 9, 2020 · AXO-AAV-GM2 is the first investigational gene therapy to achieve IND clearance for Tay-Sachs and Sandhoff diseases. The Company received a letter from the FDA...
Axovant CEO David Hung quits after Alzheimer's drug failure
2 days ago · Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s – and the fall-out is still being felt, with CEO David Hung deciding to walk out.
Fast track for dementia drug good news for Axovant and new CEO
Jun 9, 2025 · Axovant has gained FDA fast track designation for its pipeline drug nelotanserin, a treatment for visual hallucinations suffered by people with dementia with Lewy bodies (DLB).
Axovant pushes on with Parkinson's gene therapy, despite …
Oct 7, 2020 · Axovant has said it plans to continue developing its Parkinson’s Disease gene therapy after reporting supportive data from a small cohort of patients from a phase 2 trial.
Axovant axes neuroscience drug, focuses on gene therapies
4 days ago · Swiss biotech Axovant started the year badly, dropping its Alzheimer’s drug intepirdine after it failed in a trial, and it has ended with another flop from a neuroscience drug, …
FDA clears IND application for Tay-Sachs gene therapy
Nov 9, 2020 · The Axovant therapy, AXO-AAV-GM2, is the first investigational gene therapy to achieve IND clearance for Tay-Sachs and Sandhoff. The clinical hold was in place to resolve …
TanganSakti99 - Situs Slot Online Gacor 2025 dengan Bonus
TanganSakti99 adalah platform slot online gacor 2025 terpercaya yang juga menyediakan voucher game digital terlengkap. Mainkan slot RTP tinggi dan klaim bonus menarik setiap hari!
